The FDA has accepted a Biologics License Application for imsidolimab to treat generalized pustular psoriasis, a rare inflammatory skin condition.
Accelerated review was enabled by the Commissioner’s National Priority Voucher Pilot Program, targeting high unmet need and ...
Argenx Se ( (ARGX)) has provided an update. On March 6, 2026, Argenx announced it will present extensive new data on VYVGART and its neurology pipeline at the American Academy of Neurology Annual ...
Vertex Pharmaceuticals Inc. (VRTX) announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial evaluating povetacicept ...
Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens83.3% of ...
4d
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical ...
Dermatomyositis is a rare autoimmune disease that typically affects the skin, muscle and respiratory system. Patients with dermatomyositis usually require prompt treatment with intense ...
This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after semaglutide use. She was found to have progressive dysphagia, dysphonia, proximal ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from a pre-specified Week 36 interim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results